Hantavirus rapid and molecular diagnostic kits / Courtes of GC Medical Science
Hantavirus rapid and molecular diagnostic kits / Courtes of GC Medical Science

GC Medical Science said Wednesday it has secured export approval from the Ministry of Food and Drug Safety for rapid and molecular diagnostic kits for hantavirus, paving the way for overseas expansion.

The company received export approval for its rapid diagnostic kit on Oct. 30, followed by approval for its polymerase chain reaction (PCR)-based molecular diagnostic kit on Nov. 12.

The additions expand its hantavirus testing portfolio beyond its existing enzyme-linked immunosorbent assay (ELISA)-based research diagnostic reagents.

The rapid test uses an immune response to deliver results in a short time, while the molecular test uses PCR technology to directly detect specific viral genes.

GC Medical Science currently holds approvals for seven infectious disease diagnostic products: six for export, including four dengue fever kits, one chikungunya kit and one mpox kit, as well as one malaria diagnostic kit for domestic use. The two newly approved hantavirus products further strengthen its portfolio.

The company plans to continue developing and commercializing diagnostic products for major infectious diseases.

Leveraging its existing overseas sales network, it aims to expand the countries and product categories covered by its new kits and increase its presence and revenue in the global infectious disease diagnostics market.

“We will continue research and development and commercialization of diagnostic products for major infectious diseases, including mpox and Ebola, while leveraging our established overseas sales network to expand our markets and product portfolio,” a GC Medical Science official said.



Source link